Goldman Sachs Assumes BioMarin Pharmaceutical Inc. (BMRN) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Jefferies Survey Suggests Positive Expectations for BioMarin (BMRN) Ahead of Data on 11/24
November 19, 2015 7:42 AM ESTIn a turn of events, Jefferies analyst, Gena Wang, surveyed 58 investors to find out expectations for upcoming therapy results and found the buy-sides expectations of 62/28/10% probability for positive/mixed/negative outcomes for BioMarin Pharma's (NASDAQ: BMRN) Kyndrisa (drisapersen). The results are expected... More
